NasdaqCM - Delayed Quote USD

Fortress Biotech, Inc. (FBIO)

1.7900 -0.0200 (-1.10%)
At close: April 24 at 4:00 PM EDT
1.8000 +0.01 (+0.56%)
After hours: April 24 at 6:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
84,513.0000
84,513.0000
75,743.0000
68,791.0000
45,599.0000
Cost of Revenue
26,660.0000
26,660.0000
30,775.0000
32,084.0000
14,594.0000
Gross Profit
57,853.0000
57,853.0000
44,968.0000
36,707.0000
31,005.0000
Operating Expense
200,195.0000
200,195.0000
248,532.0000
215,708.0000
125,275.0000
Operating Income
-142,342.0000
-142,342.0000
-203,564.0000
-179,001.0000
-94,270.0000
Net Non Operating Interest Income Expense
-12,312.0000
-12,312.0000
-12,244.0000
-14,659.0000
-13,808.0000
Other Income Expense
1,021.0000
1,021.0000
2,344.0000
29,307.0000
5,229.0000
Pretax Income
-153,633.0000
-153,633.0000
-213,464.0000
-164,353.0000
-102,849.0000
Tax Provision
521.0000
521.0000
449.0000
473.0000
136.0000
Net Income Common Stockholders
-68,669.0000
-68,669.0000
-94,607.0000
-64,703.0000
-46,526.0000
Diluted NI Available to Com Stockholders
-68,669.0000
-68,669.0000
-94,607.0000
-64,703.0000
-46,526.0000
Basic EPS
-8.47
--
-15.97
-11.85
-9.75
Diluted EPS
-8.47
--
-15.97
-11.85
-9.75
Basic Average Shares
8,110.9060
--
5,924.9670
5,446.6810
4,800.3450
Diluted Average Shares
8,110.9060
--
5,924.9670
5,446.6810
4,800.3450
Total Operating Income as Reported
-142,342.0000
-142,342.0000
-203,564.0000
-188,541.0000
-94,270.0000
Total Expenses
226,855.0000
226,855.0000
279,307.0000
247,792.0000
139,869.0000
Net Income from Continuing & Discontinued Operation
-60,637.0000
-60,637.0000
-86,575.0000
-64,703.0000
-46,526.0000
Normalized Income
-64,131.9600
-64,131.9600
-87,466.9100
-94,010.0000
-51,755.0000
Interest Income
3,003.0000
3,003.0000
1,398.0000
649.0000
1,518.0000
Interest Expense
11,915.0000
11,915.0000
10,417.0000
11,394.0000
9,704.0000
Net Interest Income
-12,312.0000
-12,312.0000
-12,244.0000
-14,659.0000
-13,808.0000
EBIT
-141,718.0000
-141,718.0000
-203,047.0000
-152,959.0000
-93,145.0000
EBITDA
-133,643.0000
-133,643.0000
-193,694.0000
-146,168.0000
-87,820.0000
Reconciled Cost of Revenue
26,660.0000
26,660.0000
30,775.0000
32,084.0000
14,594.0000
Reconciled Depreciation
8,075.0000
8,075.0000
9,353.0000
6,791.0000
5,325.0000
Net Income from Continuing Operation Net Minority Interest
-60,637.0000
-60,637.0000
-86,575.0000
-64,703.0000
-46,526.0000
Total Unusual Items Excluding Goodwill
4,424.0000
4,424.0000
1,129.0000
29,307.0000
5,229.0000
Total Unusual Items
4,424.0000
4,424.0000
1,129.0000
29,307.0000
5,229.0000
Normalized EBITDA
-138,067.0000
-138,067.0000
-194,823.0000
-175,475.0000
-93,049.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
--
--
Tax Effect of Unusual Items
929.0400
929.0400
237.0900
--
--
12/31/2020 - 11/17/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MBIO Mustang Bio, Inc.
0.3501
-2.67%
 
SLN Silence Therapeutics plc
22.27
-1.07%
 
CKPT Checkpoint Therapeutics, Inc.
1.4400
+0.35%
 
ATXI Avenue Therapeutics, Inc.
0.0943
-29.63%
 
EYEN Eyenovia, Inc.
0.5835
+7.54%
 
ALT Altimmune, Inc.
7.08
-6.47%
 
ALVR AlloVir, Inc.
0.7800
-1.38%
 
OCUP Ocuphire Pharma, Inc.
1.5300
-0.65%
 
SLNCF Silence Therapeutics plc
8.00
0.00%
 
BTAI BioXcel Therapeutics, Inc.
2.7100
-8.75%